N-Methyl-D-aspartate receptor participation in Parkinson's disease, a neurodegenerative disorder.
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D002375:Catalepsy / Q000139:chemically induced / Q000188:drug therapy*; D016291:Dizocilpine Maleate / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology; D007649:Ketamine / Q000494:pharmacology; D051379:Mice; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010302:Parkinson Disease, Secondary / Q000188:drug therapy* / Q000503:physiopathology; D010546:Perphenazine / Q000494:pharmacology; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000502:physiology*; D013239:Stereotyped Behavior / Q000187:drug effects*
D000978:Antiparkinson Agents; D001552:Benzazepines; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; D007649:Ketamine; D016291:Dizocilpine Maleate; D010546:Perphenazine; D006220:Haloperidol; D001058:Apomorphine